Can Biomarkers Predict Successful Tapering of Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs in Patients with Rheumatoid Arthritis Achieving Stable Clinical Remission?
It is now accepted that sustained remission is the key treatment goal for rheumatoid arthritis (RA). The availability of biologic therapies and the use of targeted treatment strategies has led to increasing numbers of patients achieving remission; however, specific guidance for the management of patients with RA in sustained clinical remission, treated with conventional synthetic disease-modifying anti-rheumatic drugs (cs-DMARDs), is lacking.